Failing to achieve a nadir prostate-specific antigen after combined androgen blockade: Predictive factors

International Journal of Urology

Volumn 16, Issue 8, 2009, Pages 670-675

  Park, Seung Chol ^a   Rim, Joung Sik ^a   Choi, Han Yong ^b   Kim, Choung Soo ^c   Hong, Sung Joon ^d   Kim, Wun Jae ^e   Lee, Sang Eun ^f   Song, Jae Mann ^g   Yoon, Jin Han ^h  

^a Wonkwang University   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c University of Ulsan   (South Korea)

^d Yonsei University   (South Korea)

^e Chungbuk National University   (South Korea)

^f Seoul National University   (South Korea)

^g Yonsei University Wonju   (South Korea)

^h Dong A University   (South Korea)

Author keywords

Androgen; Progression; Prostate cancer; Prostate specific antigen

Indexed keywords

ALKALINE PHOSPHATASE; BICALUTAMIDE; CREATININE; FLUTAMIDE; GOSERELIN; HEMOGLOBIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

ADJUVANT THERAPY; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIANDROGEN THERAPY; ARTICLE; BONE METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CREATININE BLOOD LEVEL; FOLLOW UP; GLEASON SCORE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RETROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; DISEASE PROGRESSION; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; ORCHIECTOMY; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 68749093181     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2009.02329.x     Document Type: Article

References (22)

1. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann. Oncol. 2005 16 : 481 8.
2. Ministry of Health and Welfare Republic of Korea. 2002 Annual Report of the Korea Central Cancer Registry. Seoul : Ministry of Health and Welfare Republic of Korea, 2002 11 14.
3. Korea National Statistical Office. Annual Report on the Cause of Death Statistics (Based on Vital Registration) 2005. Seoul : Korea National Statistical Office, 2005.
4. Akaza H, Yamaguchi A, Matsuda T et al. Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a lutenizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients. Jpn J. Clin. Oncol. 2004 34 : 20 8.
5. Arai Y, Akaza H, Deguchi T et al. Evaluation of quality of life in patients with previous untreated advanced prostate cancer receiving maximum androgen blockade therapy or LHRHa monotherapy: a multicenter, randomized, double-blind, comparative study. J. Cancer Res. Clin. Oncol. 2008 134 : 1385 96.
6. Miller JI, Ahmann FR, Drach GW et al. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. J. Urol. 1992 147 : 956 61.
7. Benaim EA, Pace CM, Lam PO et al. Nadir prostate-specific antigen as a predictor of progression to androgen-independent prostate cancer. Urology 2002 59 : 73 8.
8. Kwak C, Jeong SJ, Park MS et al. Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer J. Urol. 2002 168 : 995 1000.
9. Morote J, Trilla E, Esquena S et al. Nadir prostate-specific antigen best predicts the progression to androgen-independent prostate cancer. Int. J. Cancer 2004 108 : 877 81.
10. Suzuki H, Okihara K, Miyake H et al. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximal androgen blockade. J. Urol. 2008 180 : 921 7.
11. Benaim EA, Pace CM, Roehrborn CG. Gleason score predicts androgen independent progression after androgen deprivation therapy. Eur. Urol. 2002 42 : 12 17.
12. Soga N, Onishi T, Arima K et al. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy. Int. J. Urol. 2007 14 : 192 6.
13. Collette L, de Reijke TM, Schroder FH Members of the EORTC Genito-Urinary Group. Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892). Eur. Urol. 2003 44 : 182 9.
14. Siddall JK, Hetherington JW, Cooper EH et al. Biochemical monitoring of carcinoma of prostate treated with an LH-RH analogue (Zoladex). Br. J. Urol. 1986 58 : 676 82.
15. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 2004 351 : 1502 12.
16. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 2004 351 : 1513 20.
17. Hussain M, Tangen CM, Higano C et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J. Clin. Oncol. 2006 24 : 3984 90.
18. D'Amico AV, Saegaert T, Chen MH et al. Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer. Cancer 2002 95 : 275 80.
19. Beer TM, Tangen CM, Bland LB et al. Prognostic value of anemia in newly diagnosed metastatic prostate cancer: a multivariate analysis of Southwest Oncology Group Study 8894. J. Urol. 2004 172 : 2213 17.
20. Beer TM, Tangen CM, Bland LB et al. The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer: a multivariate analysis of Southwest Oncology Group Study 8894. Cancer 2006 107 : 489 96.
21. Means RT Jr., Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1992 80 : 1639 47.
22. Silvestris F, Tucci M, Quatraro C et al. Recent advances in understanding the pathogenesis of anemia in multiple myeloma. Int. J. Hematol. 2003 78 : 121 5.